HRMY — Harmony Biosciences Holdings Share Price
0.000.00%
Last trade - 00:00- $1.82bn
- $1.64bn
- $582.02m
- 86
- 71
- 63
- 85
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.97 | ||
| PEG Ratio (f) | 0.39 | ||
| EPS Growth (f) | 34.88% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.32 | ||
| Price to Tang. Book | 4.45 | ||
| Price to Free Cashflow | 8.24 | ||
| Price to Sales | 2.77 | ||
| EV to EBITDA | 7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 27.99% | ||
| Return on Equity | 28.73% | ||
| Operating Margin | 31.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6 | 159.74 | 305.44 | 437.86 | 582.02 | 709.82 | 839.29 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +199.24 | -24.09 | -1.26 | +75.07 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Directors
- Jeffrey Aronin NEC
- John Jacobs PRE (54)
- Sandip Kapadia CFO (51)
- Jeffrey Dierks SVP (49)
- Jeffrey Dayno OTH (63)
- Andrew Serafin OTH (46)
- Antonio Gracias IND (50)
- R. Mark Graf IND (56)
- Jack Nielsen IND (57)
- Aaron Royston IND
- Juan Sabater IND (56)
- Gary Sender IND (59)
- Linda Szyper IND (55)
- Andreas Wicki IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 25th, 2017
- Public Since
- August 19th, 2020
- No. of Shareholders
- 35
- No. of Employees
- 246
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 56,791,861
- Address
- 630 W Germantown Pike, Suite 215, PLYMOUTH MEETING, 19462
- Web
- https://www.harmonybiosciences.com/
- Phone
- +1 4845399800
- Auditors
- Deloitte & Touche LLP
Upcoming Events for HRMY
Q3 2024 Harmony Biosciences Holdings Inc Earnings Release
Similar to HRMY
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Harmony Biosciences Holdings share price?
As of Today at 15:04 UTC, shares in Harmony Biosciences Holdings are trading at $30.13. This share price information is delayed by 15 minutes.
How has the Harmony Biosciences Holdings share price performed this year?
Shares in Harmony Biosciences Holdings last closed at $30.13 and the price had moved by -18.37% over the past 365 days. In terms of relative price strength the Harmony Biosciences Holdings share price has underperformed the S&P500 Index by -35.04% over the past year.
What are the analyst and broker recommendations for Harmony Biosciences Holdings?
The overall consensus recommendation for Harmony Biosciences Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Harmony Biosciences Holdings dividend yield?
Harmony Biosciences Holdings does not currently pay a dividend.
Does Harmony Biosciences Holdings pay a dividend?
Harmony Biosciences Holdings does not currently pay a dividend.
When does Harmony Biosciences Holdings next pay dividends?
Harmony Biosciences Holdings does not currently pay a dividend.
How do I buy Harmony Biosciences Holdings shares?
To buy shares in Harmony Biosciences Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Harmony Biosciences Holdings?
As of the previous close price of $30.13, shares in Harmony Biosciences Holdings had a market capitalisation of $1.71bn.
Where are Harmony Biosciences Holdings shares listed?
Here are the trading details for Harmony Biosciences Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: HRMY
What kind of share is Harmony Biosciences Holdings?
Based on an overall assessment of its quality, value and momentum Harmony Biosciences Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Harmony Biosciences Holdings share price forecast for 2024?
The analyst consensus target price for shares in Harmony Biosciences Holdings is $43.00. That is 42.71% above the last closing price of $30.13.
Analysts covering Harmony Biosciences Holdings currently have a consensus Earnings Per Share (EPS) forecast of $2.23 for the next financial year.
What is the trend in the Harmony Biosciences Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Harmony Biosciences Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -18.09%.
As of the last closing price of $30.13, shares in Harmony Biosciences Holdings were trading -1.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Harmony Biosciences Holdings PE Ratio?
The Harmony Biosciences Holdings PE ratio based on its reported earnings over the past 12 months is 9.97. The shares last closed at $30.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Harmony Biosciences Holdings?
Harmony Biosciences Holdings' management team is headed by:
- Jeffrey Aronin - NEC
- John Jacobs - PRE
- Sandip Kapadia - CFO
- Jeffrey Dierks - SVP
- Jeffrey Dayno - OTH
- Andrew Serafin - OTH
- Antonio Gracias - IND
- R. Mark Graf - IND
- Jack Nielsen - IND
- Aaron Royston - IND
- Juan Sabater - IND
- Gary Sender - IND
- Linda Szyper - IND
- Andreas Wicki - IND